# Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium

> **NCT00004856** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 40 (actual)

## Conditions studied

- Distal Urethral Cancer
- Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
- Proximal Urethral Cancer
- Recurrent Bladder Cancer
- Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
- Recurrent Urethral Cancer
- Stage IV Bladder Cancer
- Transitional Cell Carcinoma of the Bladder
- Urethral Cancer Associated With Invasive Bladder Cancer

## Interventions

- **BIOLOGICAL:** trastuzumab

## Key facts

- **NCT ID:** NCT00004856
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-07
- **Primary completion:** 2002-07
- **Final completion:** —
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2013-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004856, "Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00004856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*